Femasys (FEMY) vs PAVmed (PAVM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PAVmed (PAVM) has outperformed Femasys (FEMY) over the past year, losing 81.1% versus a loss of 82.9%. Over five years, FEMY leads with a -98.5% price change compared with -99.9% for PAVM. PAVmed is the larger company by market cap ($21.5 million vs $17.1 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FEMY | PAVM |
|---|---|---|
| Share price | $2.05 | $2.69 |
| Market cap | $17.13M | $21.51M |
| 1-day change | +2.25% | -1.82% |
| YTD return | -82.25% | -59.43% |
| 1-year return | -82.87% | -81.12% |
| 5-year return | -98.54% | -99.90% |
| EPS (TTM) | $-3.28 | $-14.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.20 | $28.44 |
| 52-week low | $1.94 | $2.60 |
| Distance from 52-week high | -90.79% | -90.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +600.73% | +1256.88% |
| Average volume | 722.09K | 30.34K |
| Shares outstanding | 8.38M | 8.00M |
| Employees | 51 | 41 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Femasys
FEMY stock →Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.
Health Care · Medical/Dental Instruments · 51 employees
About PAVmed
PAVM stock →PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States.
Health Care · Medical/Dental Instruments · 41 employees
FEMY vs PAVM FAQ
Which is bigger, Femasys or PAVmed?
PAVmed (PAVM) is larger, with a market capitalization of $21.51M compared with $17.13M for Femasys (FEMY).
Which stock has performed better over the past year, FEMY or PAVM?
PAVM returned -81.12% over the past 12 months, compared with -82.87% for FEMY (price return, excluding dividends). Past performance does not predict future results.
Are Femasys and PAVmed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.